[
  {
    "ts": null,
    "headline": "Large-cap biotech is a sector to watch for investors: Analysts",
    "summary": "Large-cap biotechs are a potential new asset class as China and D.C. pressure Big Pharma to invest elsewhere.",
    "url": "https://finnhub.io/api/news?id=0662f07a31d05278cb660cdf2621d1dc4a73cf29cd67af073f9e563f506cfd9c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756644000,
      "headline": "Large-cap biotech is a sector to watch for investors: Analysts",
      "id": 136588775,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Large-cap biotechs are a potential new asset class as China and D.C. pressure Big Pharma to invest elsewhere.",
      "url": "https://finnhub.io/api/news?id=0662f07a31d05278cb660cdf2621d1dc4a73cf29cd67af073f9e563f506cfd9c"
    }
  },
  {
    "ts": null,
    "headline": "HSBC Upgrades Eli Lilly (LLY) to Hold, Lifts Price Target to $700",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best stocks for a 20-year long-term stock portfolio. Eli Lilly has substantially underperformed this year with YTD decline of over 5%. On August 8, its shares touched $625-$626, levels last seen in 2024. However, it has since appreciated by nearly 17% as investor sentiment improved. August 27, HSBC analyst […]",
    "url": "https://finnhub.io/api/news?id=28ee6ffb83d1b9f6bbbfaed9e7a90ca70692c84c2410860d00edd236a44c80b1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756617406,
      "headline": "HSBC Upgrades Eli Lilly (LLY) to Hold, Lifts Price Target to $700",
      "id": 136596091,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best stocks for a 20-year long-term stock portfolio. Eli Lilly has substantially underperformed this year with YTD decline of over 5%. On August 8, its shares touched $625-$626, levels last seen in 2024. However, it has since appreciated by nearly 17% as investor sentiment improved. August 27, HSBC analyst […]",
      "url": "https://finnhub.io/api/news?id=28ee6ffb83d1b9f6bbbfaed9e7a90ca70692c84c2410860d00edd236a44c80b1"
    }
  }
]